Progressive Supranuclear Palsy (PSP): Symptoms, Standard Care, and Investigational Stem Cell Research

Progressive supranuclear palsy (PSP) is a rare, progressive neurodegenerative disease that affects movement, balance, eye movement, speech, and swallowing, caused by abnormal accumulation of tau protein in the brain. There is currently no disease-modifying treatment; standard care focuses on symptom management, fall prevention, and supportive therapies. Stem cell therapy for PSP is investigational, but it’s worth noting this is one of the more researched investigational areas among the rare conditions we discuss — a Phase I randomized, placebo-controlled safety trial has been conducted in PSP patients, alongside a published case report describing functional improvement in an individual patient. At Viezec, we offer this as a supportive, investigational option alongside standard neurological care, with the clear understanding that individual response varies from patient to patient and is not guaranteed.

PSP belongs to a family of neurodegenerative diseases called tauopathies, in which abnormal tau protein accumulates in brain cells, particularly affecting areas controlling movement, balance, and eye movement. It’s sometimes misdiagnosed initially as Parkinson’s disease due to overlapping early symptoms, though PSP typically progresses more rapidly and responds poorly to standard Parkinson’s medications.

• Frequent, unexplained falls, often backward, especially early in the disease course
• Difficulty with vertical eye movement, particularly looking downward — a hallmark feature that helps distinguish PSP from other parkinsonian conditions
• Stiffness and slowness of movement
• Slurred speech and difficulty swallowing, which increases over time
• Changes in mood, behavior, and cognition
• A characteristic “surprised” or staring facial expression due to reduced blinking and facial muscle rigidity

Diagnosis relies primarily on clinical examination by a neurologist familiar with movement disorders, focusing on the characteristic pattern of falls, eye movement abnormalities, and limited response to levodopa (a standard Parkinson’s medication). MRI can show characteristic brain changes in later stages, though early-stage imaging may appear normal, making clinical assessment central to diagnosis.

Standard care

There is currently no treatment that stops or reverses PSP’s underlying progression. Management focuses on:

• Levodopa trial — sometimes offers modest, partial symptom benefit, though PSP generally responds less well to this medication than Parkinson’s disease does
• Physical and occupational therapy — focused heavily on fall prevention, given how central falls are to PSP-related injury risk
• Speech and swallowing therapy — to manage progressive speech and swallowing difficulties and reduce aspiration risk
• Botulinum toxin injections — sometimes used for specific symptoms like eyelid spasm
• Assistive devices and home safety modifications — to reduce fall risk as balance worsens
• Multidisciplinary supportive care — coordinated neurology, therapy, and caregiver support, since PSP significantly affects both patients and families over its course

Active drug research is also underway targeting the underlying tau pathology directly — for example, a current multi-center platform trial is testing a tau-targeted immunotherapy in PSP patients, reflecting that this remains an area of real ongoing scientific investment, even though no disease-modifying therapy has yet succeeded in large trials.

This is a genuinely more researched area than many other rare conditions, and worth walking through directly:

A real Phase I clinical trial has been conducted. Researchers in Italy designed and ran a randomized, placebo-controlled, double-blind Phase I study testing autologous bone marrow-derived mesenchymal stem cells (MSCs), delivered via intra-arterial injection, in PSP patients — describing it as the first trial of its kind in a “no-option” parkinsonism. A subsequent report on this pilot feasibility study, involving seven patients, focused specifically on establishing safety. The proposed mechanism is that MSCs may help through secretion of neurotrophic factors and reduction of oxidative stress and cell loss in affected brain regions — a plausible, biologically reasoned mechanism under real investigation, not yet a proven treatment pathway.

A published case report described meaningful individual improvement. A 71-year-old patient with PSP treated with autologous adipose-derived mesenchymal stem cells (intravenous and intrathecal) showed no significant adverse events and demonstrated functional improvement on standardized clinical scales during six months of follow-up, including improved balance scale scores and maintained grip strength. The authors described this as encouraging, while explicitly calling for larger studies — a single case report, however positive, is not the same as proof of consistent efficacy across patients.

What this means honestly: PSP is one of the more actively studied conditions in this space, with real trial infrastructure and at least one detailed, positive individual case. But the evidence remains early-phase and safety-focused overall, and individual results — as seen even within this small body of research — can differ meaningfully from patient to patient.

Given this evidence, we present stem cell therapy for PSP as an investigational, supportive option:

• We discuss the specific research behind it, including both the Phase I trial and case report evidence, during case review
• We’re clear that response varies from patient to patient — some patients and reported cases have shown functional improvement, while broader, larger-scale efficacy has not yet been established
• This is offered alongside, not instead of, standard neurological care, fall-prevention therapy, and multidisciplinary support
• We do not present this as a cure or guaranteed outcome, given the current state of evidence

• Common types of autoimmune diseases
• Peripheral artery disease: symptoms, causes, diagnosis, treatment
• Safety & Guarantees FAQ

Have questions about your specific case? Book a free case review and our medical team will walk you through the current research, including the specific trial and case data referenced here, and what a realistic expectation looks like for your situation.